<DOC>
	<DOCNO>NCT01288378</DOCNO>
	<brief_summary>RATIONALE : Caspofungin acetate may effective treat fungal infection patient acute myeloid leukemia myelodysplastic syndrome receive treatment cancer . It yet know whether caspofungin acetate effective treatment start development fever infection show laboratory test , chest x-ray , CT scan . PURPOSE : This randomized phase III trial study best time start caspofungin acetate therapy treat patient acute myeloid leukemia myelodysplastic syndrome newly diagnose first relapse .</brief_summary>
	<brief_title>Empirical Versus Preemptive Antifungal Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare empirical approach ( i.e. , fever drive ) versus preemptive approach ( i.e. , diagnostic driven ) , start antifungal therapy caspofungin acetate , patient acute myeloid leukemia myelodysplastic syndrome start chemotherapy ( attain remission induction ) myeloablation ( prepare allogeneic hematopoietic stem cell transplantation ) newly diagnose disease disease first relapse . Secondary - To evaluate clinical validity utility standardize Aspergillus PCR assay . - To evaluate clinical validity utility beta-D-glucan . - To determine occurrence single nucleotide polymorphism ( SNPs ) predictive value SNPs identify patient high risk develop invasive fungal infection . OUTLINE : This multicenter study . Patients stratify accord institution , prior allogeneic stem cell transplantation ( yes v ) , type air flow ( laminar air flow v high-efficiency particulate air ) . Patients randomize 1 2 treatment arm . - Arm A ( Empirical approach ) : Patients start caspofungin acetate treatment one follow criterion meet : - Presence unexplained persistent fever refractory 4 full day broad-spectrum antibacterial therapy follow regimen either alone combination aminoglycoside glycopeptide : - Ceftazidime - Cefepime - Piperacillin/tazobactam - Imipenem-cilastatin - Meropenem - New fever occur &gt; 2 day resolution first fever continue broad-spectrum antibacterial therapy define obvious cause document fungal infection exclude Patients receive caspofungin acetate IV daily . Treatment continue neutrophil recovers . - Arm B ( Preemptive approach ) : Patients start caspofungin acetate treatment least one follow criteria* meet : - Single plasma serum galactomannan ELISA index &gt; 0.5 - New pulmonary infiltrate chest x-ray IFD readily exclude - New dense well-circumscribed lesion without halo sign , CT scan , consistent IFD - Aspergillus sp . recovered culture sputum Patients receive caspofungin acetate IV daily . Treatment continue neutrophil recovers . NOTE : *These criterion sufficient warrant preemptive caspofungin acetate therapy : skin lesion evocative IFD , sinusitis orbititis , hepatosplenic abscess ( hypodensities CT scan ) , unexplained persistent fever 7 day recurrent fever whatever duration . All patient undergo blood sample collection periodically detection galactomannan beta-D-glucan detection single nucleotide polymorphism . Some patient undergo blood sample collection detection Aspergillus via PCR . An economic evaluation perform cost-effectiveness analysis . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) Newly diagnose disease disease first relapse hematological remission last minimum 6 month AND meet one follow criterion : Starting remissioninduction chemotherapy within 3 day prior study randomization Starting myeloablative condition regimen prepare first allogeneic hematopoietic stem cell transplantation within 3 day prior study randomization Planning hospital admission duration neutropenic phase ( ANC &lt; 0.5 x 10^9 /L ) Planning receive oral intravenous fluconazole Candida prophylaxis dose 400 mg/day Fluconazole discontinue caspofungin acetate administration No previous current history proven probable invasive fungal disease ( IFD ) PATIENT CHARACTERISTICS : See Disease Characteristics Not pregnant nursing Negative pregnancy test Fertile patient muse use effective contraception least 3 month completion study therapy No current clinical diagnosis pneumonia No serious , uncontrolled , concomitant disease comorbidity , opinion investigator , may compromise adherence study protocol No history allergy adverse reaction echinocandin drug ( i.e. , caspofungin acetate , micafungin , anidulafungin ) No hypersensitivity caspofungin active substance excipients No inadequately treat infection No document HIV infection No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule No history liver cirrhosis severe hepatic insufficiency ( i.e. , Child Pugh Class C , D , E ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent participation another clinical trial use investigational drug infectious diseases No concurrent systemic antifungal therapy ( oral intravenous )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>fungal infection</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>